Table 4.
Molecular characterization of patients with endometrial adenocarcinoma (n = 22) and outcome.
| MMRd (n = 4) |
POLE- Mutated (n = 0) |
p53 Abnormal (n = 1) |
p53 Wild Type (n = 17) |
Total (n = 22) |
|
|---|---|---|---|---|---|
| Progression or requireddefinitive treatment, n (%) | |||||
| No | 3 (75.0) | - | 0 (0) | 13 (76.5) | 16 (72.7) |
| Yes | 1 (25.0) | - | 1 (100.0) | 4 (23.5) | 6 (27.3) |
|
Type of definitive therapy n (%) |
n = 1 |
n = 1 |
n = 4 |
n = 6 |
|
| Surgery | 1 (100.0) | - | 1 (100.0) | 4 (100.0) | 6 (100.0) |
| Radiation | 0 (0) | - | 0 (0) | 0 (0) | 0 (0.0) |
|
Final diagnosis on hysterectomy specimen n (%) |
n = 1 |
n = 1 |
n = 4 |
n = 6 |
|
| No residual disease | 0 (0.0) | - | 0 (0.0) | 1 (25.0) | 1 (16.7) |
| EIN | 0 (0.0) | - | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Cancer | 1 (100.0) | - | 1 (100.0) | 3 (75.0) | 5 (83.33) |
Abbreviations: MMRd: mismatch repair-deficient; EIN: endometrial intraepithelial neoplasia.